Cardiac and Pericardial 18F-FDG Uptake on Oncologic PET/CT: Comparison with Echocardiographic Findings
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
BACKGROUND: Interpretation of cardiac uptake on 18-fluorodeoxyglucose positron emissiontomography/computed tomography (18F-FDG PET/CT) is often confounded by intensephysiological FDG uptake and numerous benign conditions. The aim of the study was todescribe the echocardiographic features in concordance with cardiac and pericardial 18F-FDGuptake on whole-body oncology PET/CT. METHODS: We enrolled 43 consecutive patients (34 solid tumors, 8 lymphomas and 1leukemia) who were newly diagnosed with non-cardiac malignancy showing incidentalcardiac or pericardial 18F-FDG uptake on PET/CT and underwent transthoracic Dopplerechocardiography (TTE) within 1 month of PET/CT. The maximum standardized uptake(SUVmax) of all lesions was measured. RESULTS: Fifty-six 18F-FDG uptake lesions (32 pericardium, 7 myocardium, 9 cardiacchambers and 8 great vessels) were found, and pericardial effusion was the most commonechocardiographic finding (22/43, 51.2%) among study population. Pericardial FDG uptakewas shown as pericardial effusion (68.8%), intrapericardial echogenic materials (31.3%),pericardial thickening (28.1%), hyperechogenicity of myopericardium (18.8%), and restrictedsliding movement or constrictive pericarditis (15.6%) on TTE. Lesions with regional wallmotion abnormality (p = 0.004) or constrictive pericarditis (p = 0.021) had significantlyhigher mean SUVmax than those without. Myocardial FDG uptake demonstrated pericardialeffusion (57.1%), regional wall motion abnormality (57.1%), and increased myocardial wallthickness (42.9%). All cardiac chamber FDG uptakes showed intracardiac mass on TTE. CONCLUSIONS: Cardiac or pericardial 18F-FDG uptake on oncology PET/CT showscharacteristic echocardiographic features according to which heart sites are involved.
Abstract
BACKGROUND: Interpretation of cardiac uptake on 18-fluorodeoxyglucose positron emissiontomography/computed tomography (18F-FDG PET/CT) is often confounded by intensephysiological FDG uptake and numerous benign conditions. The aim of the study was todescribe the echocardiographic features in concordance with cardiac and pericardial 18F-FDGuptake on whole-body oncology PET/CT. METHODS: We enrolled 43 consecutive patients (34 solid tumors, 8 lymphomas and 1leukemia) who were newly diagnosed with non-cardiac malignancy showing incidentalcardiac or pericardial 18F-FDG uptake on PET/CT and underwent transthoracic Dopplerechocardiography (TTE) within 1 month of PET/CT. The maximum standardized uptake(SUVmax) of all lesions was measured. RESULTS: Fifty-six 18F-FDG uptake lesions (32 pericardium, 7 myocardium, 9 cardiacchambers and 8 great vessels) were found, and pericardial effusion was the most commonechocardiographic finding (22/43, 51.2%) among study population. Pericardial FDG uptakewas shown as pericardial effusion (68.8%), intrapericardial echogenic materials (31.3%),pericardial thickening (28.1%), hyperechogenicity of myopericardium (18.8%), and restrictedsliding movement or constrictive pericarditis (15.6%) on TTE. Lesions with regional wallmotion abnormality (p = 0.004) or constrictive pericarditis (p = 0.021) had significantlyhigher mean SUVmax than those without. Myocardial FDG uptake demonstrated pericardialeffusion (57.1%), regional wall motion abnormality (57.1%), and increased myocardial wallthickness (42.9%). All cardiac chamber FDG uptakes showed intracardiac mass on TTE. CONCLUSIONS: Cardiac or pericardial 18F-FDG uptake on oncology PET/CT showscharacteristic echocardiographic features according to which heart sites are involved.
참고문헌 (24)
- Bussani R, "Cardiac metastases", J Clin Pathol, 60, pp.27~34 (2007)[DOI]
- Bisel HF, "Incidence and clinical manifestations of cardiac metastases", J Am Med Assoc, 153, pp.712~715 (1953)[DOI]
- Lam KY, "Tumors of the heart. A 20-year experience with a review of 12,485 consecutive autopsies", Arch Pathol Lab Med, 117, pp.1027~1031 (1993)
- Butany J, "A 30-year analysis of cardiac neoplasms at autopsy", Can J Cardiol, 21, pp.675~680 (2005)
- McDonnell PJ, "Involvement of the heart by malignant lymphoma: a clinicopathologic study", Cancer, 49, pp.944~951 (1982)[DOI]
- Weber WA, "Positron emission tomography as an imaging biomarker", J Clin Oncol, 24, pp.3282~3292 (2006)[DOI]
- Fischman AJ, "Positron emission tomography in the clinical evaluation of metastatic cancer", J Clin Oncol, 14, pp.691~696 (1996)[DOI]
- Fletcher JW, "Recommendations on the use of 18F-FDG PET in oncology", J Nucl Med, 49, pp.480~508 (2008)[DOI]
- fluoro-2-deoxy-D-glucose, "Nucl Med Commun", 2002, 961~965, 10.1097[DOI]
- Kaneta T, "Evaluation of the relationship between physiological FDG uptake in the heart and age, blood glucose level, fasting period, and hospitalization", Ann Nucl Med, 20, pp.203~208 (2006)[DOI]
- Fukuchi K, "Benign variations and incidental abnormalities of myocardial FDG uptake in the fasting state as encountered during routine oncology positron emission tomography studies", Br J Radiol, 80, pp.3~11 (2007)[DOI]
- Maurer AH, "How to differentiate benign versus malignant cardiac and paracardiac 18F FDG uptake at oncologic PET", CT, 2011, pp.31, 1287~1305
- Johnson MH, "Echocardiography of cardiac metastases", AJR, 141, pp.677~681 (1983)[DOI]
- Kutalek SP, "Metastatic tumors of the heart detected by two-dimensional echocardiography", Am Heart J, 109, pp.343~349 (1985)[DOI]
- Tominaga K, "The value of two-dimensional echocardiography in detecting malignant tumors in the heart", Cancer, 58, pp.1641~1647 (1986)[DOI]
- Auger D, "Cardiac masses: an integrative approach using echocardiography and other imaging modalities", Heart, 97, pp.1101~1109 (2011)[DOI]
- Lang RM, "Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", Eur Heart J Cardiovasc Imaging, 16, pp.233~270 (2015)[DOI]
- Nagueh SF, "Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging", Eur Heart J Cardiovasc Imaging, 17, pp.1321~1360 (2016)[DOI]
- Klein AL, "American Society of Echocardiography clinical recommendations for multimodality cardiovascular imaging of patients with pericardial disease: endorsed by the Society for Cardiovascular Magnetic Resonance and Society of Cardiovascular Computed Tomography", J Am Soc Echocardiogr, 26, pp.965~1012 (2013)[DOI]
- Lobert P, "Spectrum of physiological and pathological cardiac and pericardial uptake of FDG in oncology PET-CT", Clin Radiol, 68, pp.e59~e71 (2013)[DOI]
- Sheikine Y, "Integrated PET", CT in the assessment of etiology and viability in ischemic heart failure, 2008, pp.5, 136~142
- Kobylecka M, "Myocardial viability assessment in 18FDG PET", CT study (18FDG PET myocardial viability assessment), 2012, pp.15, 52~60
- Reynen K, "Metastases to the heart", Ann Oncol, 15, pp.375~381 (2004)[DOI]
- MacGee W, "Metastatic and invasive tumours involving the heart in a geriatric population: a necropsy study", Virchows Arch A Pathol Anat Histopathol, 419, pp.183~189 (1991)[DOI]